1. Medtech Insight
  2. >>Business

Fractional Flow Reserve Proves Itself Early In St. Jude’s FAME II Study

St. Jude Medical’s fractional flow reserve technology gave stenting a significant enough edge in stable coronary disease patients that a monitoring board recommended stopping the study early because it would be unethical to continue to randomize patients to the optimal medical therapy control group.

St. Jude Medical’s fractional flow reserve technology for assessing coronary artery lesions hit early success in the large FAME II study, a clear positive for the firm’s PressureWire devices and a potential catalyst for growth in stent procedures.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D